多发性脑转移患者全脑同期推量调强放疗疗效分析  

Curative Effect and Prognosis of whole Brain Simultaneous Modulated Radiotherapy for Patients with Multiple Cerebral Metastatic Carcinoma

作　　者：崔建国[1] 吴星娆[1] 夏群[1] 丁祥[1] 龙清[1] 

机构地区：[1]昆明医科大学第三附属医院放射治疗中心,云南昆明650118

出　　处：《河北医学》2014年第10期1628-1631,共4页Hebei Medicine

基　　金：云南省卫生科技计划项目;(编号:2011WS0060)

摘　　要：目的:研究全脑同期推量调强放疗(SimuLtaneous moduLated radiotherapy,SMR)对脑多发性转移癌(MuLtiple cerebral metastatic carcinoma,MCMC)患者疗效及预后情况。方法:选取我院2010年7月至2013年7月,收治的80例MCMC病患作为观察对象。以数字法随机分成两组。观察组实施全脑SMR,对照组实施常规全脑放疗。对比两组疗效以及预后情况。结果:观察组RR为72.50%(29/40),较对照组的47.50%(19/40)明显高。差异均具有统计学意义(均P<0.05)。两组病患全部顺利完成治疗,未见Ⅲ级以上NS反应以及2度以上骨髓抑制。观察组恶心、呕吐为0.93±0.15,白细胞降低为1.32±0.21,血小板下降为0.76±0.11,贫血为1.32±0.24,较对照组的1.01±0.12,1.44±0.22,0.82±0.12,1.44±0.25明显更低。结论:全脑SMR治疗MCMC,疗效显著。毒副反应患者可耐受,安全可行,值得推荐。Objective： To study the curative effect and prognosis of whole brain simultaneous modulated radiotherapy （SMR ） for multiple cerebral metastatic carcinoma （ MCMC ） patients. Method： The total of 80 MCMC patients in our hospital from July 2010 to July 2013 were randomly divided into two groups. The observation group received whole brain SMR; the control group received routine whole brain radiotherapy, compared the curative effect and prognosis of two groups. Result： The total effective rate in observation group [ 72.50% {29/40} ] was higher than the control group [47.50% { 19/40） ]. The differences were statistically significant （ P〈0.05 ）. Patients of two groups all successfully completed treatment had no neurotoxic reactions above grade III and 2 degrees of bone marrow suppression. The observation group ＇ s nausea, vomiting [0.93 ± 0.15], decreased white blood cells [1.32 ± 0.21], thrornbocytopenia [0.76 ± 0.11] , anemia [1. 32 ±0.24], were lower than the control group＇s [1.01 ± 0.12, 1.44 ± 0.22, 0.82 ± 0.12, 1.44 ±0.25]. The differences were statistically significant （P〈0.05）. Conclusion： Whole brain SMR desirable has a good effect on MCMC patients, Toxicity is acceptable. It is worthy of recommendation.

关 键 词：全脑同期推量调强放疗 脑多发性转移癌 疗效 预后 

分 类 号：R739.41[医药卫生—肿瘤]